FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why
February 2, 2024
CNBC
The FDA placed a clinical hold on DiaMedica Therapeutics Inc's (NASDAQ: DMAC ) Phase 2/3 ReMEDy2 trial evaluating DM199 to treat acute ischemic stroke patients.
The clinical hold was initiated following the company's pause in patient enrollment and submission of three serious adverse event reports related to clinically significant transient hypotension (low blood pressure) occurring shortly after initiating the ... Full story available on Benzinga.com
SweepCast
Simplest Unusual Options Activity Platform for traders. SweepCast can be used for swing or day traders who are looking to get insights on where Smart money is flowing, sign up today.